USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: EUTROPICS PHARMACEUTICALS, INC.
Address: 60 GRAMPIAM WAY
DORCHESTER, MA 02125-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $726,735.00 3
SBIR Phase II $2,857,471.00 2

Award List:

Development of small molecule inhibitors of Mcl-1 for cancer treament

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $326,983.00
Abstract:
DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1(Mcl-1), a member of this protein family, is a key regulator of lymphoid cancers including B-cell lymphoma, mul tiple myeloma, and chronic lymphocytic… More

BH3 Profiling as a Companion Diagnostic For Velcade

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael Cardone – (617) 314-6431
Award Amount: $199,860.00
Abstract:
There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating multiple myeloma. Eutropics is uniquely positioned to improve therapy efficacy for multiple myeloma by using a proprietary assay that provides a novel predictive… More

Development of small molecule inhibitor of Mcl-1 for cancer treatment

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael H. Cardone
Award Amount: $1,357,725.00
Abstract:
DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1 (Mcl-1), a member of this protein family, is a key regulator of lymphoid cancers including Multiple Myeloma (MM) , Non-Hodgkin's Lymphoma (NHL), and other… More

IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael Cardone – 617-714-4405
Award Amount: $1,499,746.00
Abstract:
There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve therapy efficacy… More

IGF::OT::IGF OTHER FUNCTIONS RandD- BIOMEDICAL (BASIC RESEARCH)

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael Cardone – 617-714-4405
Award Amount: $199,892.00
Abstract:
There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Acute Myelogenous Leukemia (AML) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve… More